OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 16:09 UTC. Every row links to its source record.

KAT6A lysine acetyltransferase 6A

ENSG00000083168 · protein coding · Open Targets profile

Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro) (PubMed:11742995, PubMed:11965546). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity (PubMed:11965546). May act as a transcriptional coactivator for RUNX1 and RUNX2 (PubMed:12771199). Acetylates p53/TP53 at 'Lys-120' and 'Lys-382' and controls its transcriptional activity via association with PML (PubMed:23431171). May play a role in leukemogenic gene transcription (PubMed:39794553). {ECO:0000269|PubMed:11742995, ECO:0000269|PubMed:11965546, ECO:0000269|PubMed:12771199, ECO:0000269|PubMed:16387653, ECO:0000269|PubMed:17925393, ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:39794553}.

In 15 of 15 cancers, the evidence for KAT6A comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751lung carcinomalung carcinomalung carcinoma: somatic 0.61esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.61colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.61nodular malignant melanomanodular malignant melanomanodular malignant melanoma: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61skin squamous cell carcinomaskin squamous cell carcinomaskin squamous cell carcinoma: somatic 0.61cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61hemangioblastomahemangioblastomahemangioblastoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61superficial spreading melanomasuperficial spreading melanomasuperficial spreading melanoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61gastric carcinomagastric carcinomagastric carcinoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand, High-Quality Ligand, High-Quality Pocket
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.04535900056362152 (upper bound 0.07915300130844116). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of KAT6A's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of KAT6A's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.